175 related articles for article (PubMed ID: 16290143)
1. Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
Shue HJ; Chen X; Schwerdt JH; Paliwal S; Blythin DJ; Lin L; Gu D; Wang C; Reichard GA; Wang H; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Nomeir AA; Morgan CA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2006 Feb; 16(4):1065-9. PubMed ID: 16290143
[TBL] [Abstract][Full Text] [Related]
2. Cyclic urea derivatives as potent NK1 selective antagonists.
Shue HJ; Chen X; Shih NY; Blythin DJ; Paliwal S; Lin L; Gu D; Schwerdt JH; Shah S; Reichard GA; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Liu F; Nomeir AA; Morgan CA; Varty GB
Bioorg Med Chem Lett; 2005 Sep; 15(17):3896-9. PubMed ID: 16019209
[TBL] [Abstract][Full Text] [Related]
3. Piperazinyl oxime ethers as NK-1 receptor antagonists.
van den Hoogenband A; van Maarseveen JH; McCreary AC; Mulder AT; van Scharrenburg GJ; van Stuivenberg HH; Zethof TJ; Zijta B; Iwema Bakker WI
Bioorg Med Chem Lett; 2006 Feb; 16(4):1045-8. PubMed ID: 16289817
[TBL] [Abstract][Full Text] [Related]
4. Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality.
Jacobsen EJ; Stelzer LS; TenBrink RE; Belonga KL; Carter DB; Im HK; Im WB; Sethy VH; Tang AH; VonVoigtlander PF; Petke JD; Zhong WZ; Mickelson JW
J Med Chem; 1999 Apr; 42(7):1123-44. PubMed ID: 10197957
[TBL] [Abstract][Full Text] [Related]
5. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.
Walpole C; Ko SY; Brown M; Beattie D; Campbell E; Dickenson F; Ewan S; Hughes GA; Lemaire M; Lerpiniere J; Patel S; Urban L
J Med Chem; 1998 Aug; 41(17):3159-73. PubMed ID: 9703462
[TBL] [Abstract][Full Text] [Related]
6. New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation.
Guerrini G; Ciciani G; Bruni F; Selleri S; Guarino C; Melani F; Montali M; Daniele S; Martini C; Ghelardini C; Norcini M; Ciattini S; Costanzo A
J Med Chem; 2010 Nov; 53(21):7532-48. PubMed ID: 20939501
[TBL] [Abstract][Full Text] [Related]
7. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807
[TBL] [Abstract][Full Text] [Related]
9. Cyclobutane derivatives as potent NK1 selective antagonists.
Wrobleski ML; Reichard GA; Paliwal S; Shah S; Tsui HC; Duffy RA; Lachowicz JE; Morgan CA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2006 Jul; 16(14):3859-63. PubMed ID: 16682196
[TBL] [Abstract][Full Text] [Related]
10. Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists.
Ohnmacht CJ; Albert JS; Bernstein PR; Rumsey WL; Masek BB; Dembofsky BT; Koether GM; Andisik DW; Aharony D
Bioorg Med Chem; 2004 May; 12(10):2653-69. PubMed ID: 15110847
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.
Drizin I; Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; DiDomenico S; Koenig JR; Turner SC; Jinkerson TK; Brown BS; Keddy RG; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter JM; Polakowski JS; Segreti JA; Jarvis MF; Faltynek CR; Lee CH
Bioorg Med Chem; 2006 Jul; 14(14):4740-9. PubMed ID: 16621571
[TBL] [Abstract][Full Text] [Related]
12. Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.
Ikeura Y; Ishichi Y; Tanaka T; Fujishima A; Murabayashi M; Kawada M; Ishimaru T; Kamo I; Doi T; Natsugari H
J Med Chem; 1998 Oct; 41(22):4232-9. PubMed ID: 9784098
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
Roppe J; Smith ND; Huang D; Tehrani L; Wang B; Anderson J; Brodkin J; Chung J; Jiang X; King C; Munoz B; Varney MA; Prasit P; Cosford ND
J Med Chem; 2004 Sep; 47(19):4645-8. PubMed ID: 15341479
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydroindolizinone NK1 antagonists.
Bao J; Lu H; Morriello GJ; Carlson EJ; Wheeldon A; Chicchi GG; Kurtz MM; Tsao KL; Zheng S; Tong X; Mills SG; DeVita RJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2354-8. PubMed ID: 20188553
[TBL] [Abstract][Full Text] [Related]
15. NK1 antagonists based on seven membered lactam scaffolds.
Elliott JM; Carlson EJ; Chicchi GG; Dirat O; Dominguez M; Gerhard U; Jelley R; Jones AB; Kurtz MM; Tsao Kl; Wheeldon A
Bioorg Med Chem Lett; 2006 Jun; 16(11):2929-32. PubMed ID: 16574413
[TBL] [Abstract][Full Text] [Related]
16. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
[TBL] [Abstract][Full Text] [Related]
17. Novel synthesis and pharmacological evaluation as alpha2-adrenoceptor ligands of O-phenylisouronium salts.
Goonan A; Kahvedzić A; Rodriguez F; Nagle PS; McCabe T; Rozas I; Erdozain AM; Meana JJ; Callado LF
Bioorg Med Chem; 2008 Sep; 16(17):8210-7. PubMed ID: 18678494
[TBL] [Abstract][Full Text] [Related]
18. New benzoyl urea derivatives as novel NR2B selective NMDA receptor antagonists.
Borza I; Greiner I; Kolok S; Galgóczy K; Ignácz-Szendrei G; Horváth C; Farkas S; Gáti T; Háda V; Domány G
Pharmazie; 2006 Sep; 61(9):799-800. PubMed ID: 17020160
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of 1,3-disubstituted cyclohexylmethyl urea and amide derivatives as non-peptidic motilin receptor antagonists.
Johnson SG; Gunnet JW; Moore JB; Miller W; Wines P; Rivero RA; Combs D; Demarest KT
Bioorg Med Chem Lett; 2006 Jul; 16(13):3362-6. PubMed ID: 16650762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
